Scholarly Index
Gemma Vilahur
Instituto de Salud Carlos III; 11,318 total citations; 264 total publications; best world rank #20
Instituto de Salud Carlos III
11,318Total citations
264Total publications
56H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 392 | ES 9 | 98.21 |
| Cardiac Ischemia and Reperfusion | Lifetime | 366 | ES 6 | 97.66 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 553 | ES 12 | 96.59 |
| Lipoproteins and Cardiovascular Health | Lifetime | 835 | ES 18 | 96.84 |
| Cardiac Fibrosis and Remodeling | Lifetime | 569 | ES 9 | 93.21 |
| Pomegranate: compositions and health benefits | Lifetime | 437 | ES 55 | 81.81 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 20 | ES 1 | 96.97 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 179 | ES 3 | 96.09 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 62 | ES 4 | 90.83 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 612 | ES 17 | 88.65 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 785 | ES 31 | 87.64 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 202 | ES 14 | 78.25 |
| Fatty Acid Research and Health | 2021-2025 | 798 | ES 43 | 70.27 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 614 | ES 18 | 63.70 |
| Signaling Pathways in Disease | 2021-2025 | 719 | ES 14 | 53.15 |